PA
PHAT icon

Profund Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Profund Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Buy
17,277
+793
+5% +$9.05K 0.01% 1105
2026
Q1 		$183K Buy
16,484
+922
+6% +$11.6K 0.01% 1040
2025
Q4 		$258K Buy
15,562
+3,392
+28% +$48.4K 0.01% 988
2025
Q3 		$143K Buy
+12,170
New +$126K ﹤0.01% 1016
2025
Q1 		– Sell
-13,310
Closed -$108K – 1077
2024
Q4 		$108K Buy
+13,310
New +$165K ﹤0.01% 1064

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Profund Advisors's PHAT Position: Q2 2026 in Review

Profund Advisors increased its Phathom Pharmaceuticals (PHAT) stake by 4.8% in Q2 2026, buying an estimated $9.05K and bringing the position to 17,277 shares worth $187K. The position accounts for 0.01% of the portfolio, ranked #1105.

Profund Advisors first reported a position in PHAT in Q4 2024 and has held it in 5 quarters since. The position peaked at $258K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Profund Advisors held 17,277 shares of Phathom Pharmaceuticals worth $187K as of Q2 2026.
  • Profund Advisors bought 793 Phathom Pharmaceuticals shares in Q2 2026, an estimated $9.05K.
  • Phathom Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1105 holding.
  • Profund Advisors first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Profund Advisors's Phathom Pharmaceuticals position peaked at $258K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.